Gastric cancer is one of the most common cancer worldwide with over 1 million new cases in 2018. In Asia, gastric cancer is the second leading cause of cancer mortality.1
While early gastric cancer diagnosis improves prognosis2 , early diagnosis has always been a challenge to physicians worldwide.

1. Reference:
2. 5 years survival > 90%.
Reference: Tan YK and Fielding JW.2006. Early diagnosis of early gastric cancer. Eur J Gastroenterol Hepatol. 18(8):821-9


White-light endoscopy is the most common method for visually diagnosing early signs of gastric cancer in hospitals. Images of the stomach lining are displayed on the system monitor to guide the doctors on the best sites to take biopsies. The biopsies will confirm the diagnosis after a few days.

The delay in diagnosis is because conventional white light endoscopy cannot accurately differentiate normal vs cancerous tissues.

Difficult to differentiate between normal tissue (left) and

cancerous tissue (right) under conventional white light endoscopy.

Normal tissue
Cancerous tissue


Raman Spectral Analysis is a technique capable of capturing molecular information associated with the cellular metabolic constituents when the tissue molecules are excited by light energy directed at the tissue.

With the technology, the system is able to help identify tissue with high probability of having gastric cancer.








White Light

Spectra IMDx enables in-vivo molecular diagnosis for early gastric cancer. Using Raman Spectroscopy, the system provides objective, real-time feedback for physician to determine risk of gastric cancer, leading to improved early gastric cancer detection.

Cancer states are considered as having dysplasia or adenocarcinoma.

Non-cancer states are considered as intestinal metaplasia or normal state.


SPECTRA IMDx™ enables in-vivo molecular diagnosis for early gastric cancer.  Using Raman spectroscopy, the system provides objective, real-time feedback for physicians to determine probability of the patient having gastric cancer, leading to improved early gastric cancer diagnosis.

SPECTRA IMDx™ classifies high grade dysplasia and gastric cancer as high risk, and gastritis, intestinal metaplasia, and low grade dysplasia as low risk. High risk lesions are generally treated with resection while low risk lesions can be closely followed up.

|                            |                                     |                                              |
Singapore Main Office

67 Ayer Rajah Crescent, #03-01/02
LaunchPad @ onenorth, Singapore 139950
China, Shanghai Office

R51, 14th Floor, 800 Shangcheng Road,
Pudong District, Shanghai
            For any enquiries, please write to and we will get back to you as soon as possible.

Disclaimer: Endofotonics products shown in this website may not be registered, approved for sale, or available for purchase in all countries where the website is accessible. Please consult your local Endofotonics representative for more information. Prior to undergoing esophago-gastro-duodenoscopy (EGD) procedures, please consult your healthcare professional to provide you with the possible risk and benefits associated with SPECTRA IMDx™ System.

HOME                TEAM                    PRODUCT                    PUBLICATIONS                     CONTACT